Sanofi Toronto facility update regarding ImmuCyst

Health Canada has completed a thorough health risk assessment of the bladder cancer treatment ImmuCyst produced at Sanofi Pasteur's manufacturing plant in Toronto. Health Canada's review has concluded that ImmuCyst should remain available to bladder cancer patients, provided the drug continues to meet quality assurance standards. Samples from lots of ImmuCyst will be evaluated for quality by both the manufacturer and Health Canada before being released for use by Canadians. Lots that are determined to meet specific standards will be made available as required. Read more here.